Dernières nouvelles pour Moderna (NASDAQ:MRNA) Stock

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Inc

MODERNA ORD

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas"> many investors&#8217; favorite stocks</a> over the last week — here&#8217;s a look at some of our top stories.
The three major stock indices extended their winning streak to six consecutive weeks, marking the longest stretch of gains for both the Dow Jones and S&amp;P 500 this year. The Dow rose 0.96%, the S&amp;P 500 increased by 0.85%, and the Nasdaq advanced 0.80%.
Retail sales in September exceeded expectations, and a significant drop in jobless claims added to the view that the U.S. economy is still robust. This strong economic momentum has led some analysts to reassess the Federal Reserve&#8217;s future course of action, with many now questioning the likelihood of additional interest rate cuts.
However, rising Treasury yields have impacted the housing market, causing a sharp increase in mortgage rates and a corresponding drop in mortgage applications. Homebuyer demand experienced its steepest decline since April 2020, as potential buyers pulled back due <a href="https://www.benzinga.com/markets/asia/24/10/41411026/bank-earnings-propel-wall-street-to-record-peaks-oil-plunges-below-70-gold-shines-at-all-time-highs">to the higher borrowing costs.</a>
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week&#8217;s most bullish and bearish posts that are worth another look.
<h3 class="wp-block-heading">The Bulls</h3>
&#8220;<a href="https://www.benzinga.com/markets/equities/24/10/41328252/apples-iphone-16-powers-record-sales-in-q3-just-behind-samsung-in-global-market-share-battle">Apple&#8217;s iPhone 16 Powers Record Sales In Q3, Just Behind Samsung In Global Market Share Battle</a>,&#8221; by <a href="https://www.benzinga.com/author/rounak-jain">Rounak Jain</a>, reports that Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) achieved record iPhone sales in Q3 2024, securing 18% global market share, just behind Samsung Electronics Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), as the global smartphone market grows by 5% year-over-year.
&#8220;<a href="https://www.benzinga.com/news/24/10/41321236/sam-altmans-oklo-jumps-on-google-nuclear-deal-whats-going-on">Sam Altman&#8217;s Oklo Jumps On Google Nuclear Deal: What&#8217;s Going On?</a>,&#8221; by <a href="https://www.benzinga.com/author/adam-eckert">Adam Eckert</a>, reports on Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares rising after Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) announced plans to use nuclear energy, with speculation that Sam Altman&#8216;s connections may position Oklo for future deals with tech giants.
&#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41374086/dogecoin-shiba-inu-pepe-may-have-overtaken-these-nasdaq-listed-companies-toward-billion-do">Dogecoin, Shiba Inu, Pepe May Have Overtaken These Nasdaq-Listed Companies Toward Billion-Dollar Valuations, But There&#8217;s A Catch</a>,&#8221; by <a href="https://www.benzinga.com/author/aniket-verma">Aniket Verma</a>, reports on how meme coins like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>), and Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) reached billion-dollar valuations faster than traditional companies like Nutanix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) and Nice Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>).
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406623/netflix-should-continue-to-outperform-6-analysts-on-streaming-stocks-q3-earnings">Netflix &#8216;Should Continue To Outperform&#8217;: 6 Analysts On Streaming Stock&#8217;s Q3 Earnings</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41342499/unlikely-s-p-500-stock-leaves-nvidia-behind-with-241-gain-in-2024">Unlikely S&amp;P 500 Stock Leaves Nvidia Behind With 241% Gain In 2024</a>
<a href="https://www.benzinga.com/markets/equities/24/10/41364980/russell-2000-poised-for-major-technical-breakout-analyst-eyes-a-trend-reversal-in-favor-of-small">Russell 2000 Poised For Major Technical Breakout: Analyst Eyes &#8216;A Trend Reversal In Favor Of Small Caps Outperforming&#8217; S&amp;P 500</a>
The Bears
&#8220;<a href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology">Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology</a>,&#8221; by <a href="https://www.benzinga.com/author/vandana-singh">Vandana Singh</a>, reports that Northwestern University has sued Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for allegedly using its lipid nanoparticle technology in COVID-19 vaccines like Spikevax without permission, seeking damages for patent infringement.
&#8220;<a href="https://www.benzinga.com/news/24/10/41385546/ftc-click-to-cancel-rule-makes-it-easy-to-end-subscriptions-what-it-means-for-netflix-planet-fitness">FTC &#8216;Click-To-Cancel&#8217; Rule Makes It Easy To End Subscriptions: What It Means For Netflix, Planet Fitness And More</a>,&#8221; by <a href="https://www.benzinga.com/author/erica-kollmann">Erica Kollmann</a>, reports that the Federal Trade Commission&#8217;s new rule aims to simplify canceling subscriptions, impacting companies like Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) and Planet Fitness Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) by requiring them to make a cancellation as easy as signing up.
&#8220;<a href="https://www.benzinga.com/news/24/10/41393244/tesla-has-a-new-chinese-electric-vehicle-competitor-how-a-company-that-used-to-sell-cheap-tvs-is-ent">Tesla Has A New Chinese Electric Vehicle Competitor: How A Company That Used To Sell Cheap TVs Is Entering EV Race</a>,&#8221; by <a href="https://www.benzinga.com/author/chris-katje">Chris Katje</a>, reports that Chinese company Skywell, known for selling affordable Skyworth TVs, unveiled the Q hatchback EV at the Paris Auto Show, marking its entry into the EV space and potentially challenging Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with competitively priced models.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/news/24/10/41354045/as-boeing-workers-enter-second-month-of-strike-rival-airbus-reportedly-plans-to-cut-2-500-jobs">As Boeing Workers Enter Second Month Of Strike, Rival Airbus Reportedly Plans To Cut 2,500 Jobs</a>
<a href="https://www.benzinga.com/news/24/10/41375934/meta-confirms-layoffs-across-instagram-whatsapp-and-reality-labs-amid-strategic-reshuffle">Meta Confirms Layoffs Across Instagram, WhatsApp And Reality Labs Amid Strategic Reshuffle</a>
<a href="https://www.benzinga.com/news/24/10/41375886/warren-buffetts-stock-sales-point-to-overvalued-market-says-hedge-fund-manager-david-einhorn-not-a-g">Warren Buffett&#8217;s Stock Sales Point To Overvalued Market, Says Hedge Fund Manager David Einhorn: &#8216;Not A Great Time To Have A Lot Of Equity Exposure&#8217;</a>
Keep up with all the latest breaking news and trading ideas by following<a href="https://twitter.com/Benzinga"> Benzinga</a><a href="http://twitter.com/Benzinga"> on Twitter</a>.
Image created using artificial intelligence via Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

News

Short Ideas

Trading Ideas

$DOGE

$PEPE

$SHIB

AAPL

GOOG

GOOGL

MRNA

NFLX

NICE

NTNX

OKLO

PLNT

SSNLF

TSLA

Benzinga Bulls And Bears: Apple, Tesla, Netflix, Oklo — And Dogecoin, Meme Coins Outpace Corporate Giants

Goldman Sachs identified 20 stocks with high short interest that could be primed for a short squeeze, particularly if upcoming earnings reports exceed expectations, <a href="https://www.benzinga.com/short-interest/most-shorted">providing opportunities for traders</a>. 
In a note shared this week, analyst John Marshall and his team saw the potential for substantial upside for this group of stocks if the current trend of short-covering continues.
<h3 class="wp-block-heading">What Is A Short Squeeze?</h3>
A short squeeze happens when a stock with high short interest sees a rapid price surge, forcing short sellers to buy back shares to cover their positions. This buying frenzy often propels the stock price even higher. 
Short sellers bet that the price of a stock will fall, borrowing shares to sell them at the current price with the intent of repurchasing them at a lower price. 
When a stock rises instead, short sellers scramble to cover their positions, accelerating the stock&#8217;s upward momentum.
Short squeezes typically occur when heavily shorted stocks see unexpected positive news or earnings results, triggering forced buying.
<h3 class="wp-block-heading">Relief Rallies On Earnings</h3>
Goldman analysts also highlighted that heavily shorted stocks tend to be more prone to &#8220;relief rallies&#8221; around earnings. 
A relief rally occurs when stocks perform better than expected after earnings, alleviating bearish concerns and pushing share prices higher.
"We see greater than normal potential for relief rallies on earnings," said Marshall.
The Goldman Sachs team screened for 20 stocks with high short interest, liquid options, upcoming earnings, and a Buy rating from their equity research department.
Analysts at Goldman Sachs recommend to buy call options in order to bet on a potential short squeeze. 
Call options give investors the right, but not the obligation, to buy a stock at a specific price within a set timeframe. This strategy limits risk while allowing for participation in any significant price increases due to a short squeeze or positive earnings surprise.
See Also: <a href="https://www.benzinga.com/markets/24/10/41302909/18-stocks-to-buy-7-to-sell-this-earnings-season-goldman-sachs-calls-it-the-year-of-the-stock-picker">18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It &#8216;The Year Of The Stock Picker&#8217;</a>
<h3 class="wp-block-heading">Goldman Sachs Names 20 Stocks Primed For Short-Squeeze Rallies</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Earnings Date</th>
<th>Short Interest (% of Float)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chewy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>)</td>
<td>Dec 4 (After Market Close)</td>
<td>10.7%</td>
</tr>
<tr>
<td>Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>Oct 22 (AMC)</td>
<td>10.6%</td>
</tr>
<tr>
<td>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>Oct 31 (Before Market Open)</td>
<td>9.1%</td>
</tr>
<tr>
<td>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)</td>
<td>Nov 6 (AMC)</td>
<td>8.4%</td>
</tr>
<tr>
<td>Dick&#8217;s Sporting Goods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>)</td>
<td>Nov 19 (BMO)</td>
<td>7.6%</td>
</tr>
<tr>
<td>Best Buy Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)</td>
<td>Nov 19 (BMO)</td>
<td>7.1%</td>
</tr>
<tr>
<td>TKO Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>)</td>
<td>Nov 6 (AMC)</td>
<td>6.8%</td>
</tr>
<tr>
<td>Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)</td>
<td>Nov 27 (BMO)</td>
<td>5.8%</td>
</tr>
<tr>
<td>ON Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>Oct 28 (BMO)</td>
<td>5.6%</td>
</tr>
<tr>
<td>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>)</td>
<td>Nov 5 (BMO)</td>
<td>5.5%</td>
</tr>
<tr>
<td>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)</td>
<td>Oct 31 (AMC)</td>
<td>5.3%</td>
</tr>
<tr>
<td>Expedia Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>)</td>
<td>Nov 7 (AMC)</td>
<td>5.2%</td>
</tr>
<tr>
<td>Vertiv Holdings Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>)</td>
<td>Oct 23 (BMO)</td>
<td>5.2%</td>
</tr>
<tr>
<td>Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>)</td>
<td>Oct 29 (BMO)</td>
<td>4.9%</td>
</tr>
<tr>
<td>First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>Oct 29 (AMC)</td>
<td>4.8%</td>
</tr>
<tr>
<td>MongoDB Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</td>
<td>Dec 3 (BMO)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>Nov 25 (AMC)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>Oct 30 (BMO)</td>
<td>4.7%</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>Nov 27 (AMC)</td>
<td>4.5%</td>
</tr>
<tr>
<td>CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>Nov 26 (AMC)</td>
<td>4.4%</td>
</tr>
</tbody>
</table>
</figure>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41314387/most-widely-hated-bull-market-reaches-2-year-milestone-top-20-s-p-500-stocks-drivin">&#8216;Most Widely Hated&#8217; Bull Market Reaches 2-Year Milestone: Top 20 S&amp;P 500 Stocks Driving The Rally</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Large Cap

Mid Cap

Tech

AFRM

CHWY

CRWD

DELL

DKNG

DLTR

ENPH

EXPE

FSLR

GNRC

SNOW

Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season

U.S. markets ended Thursday with mixed performance: the Dow Jones Industrial Average climbed 0.4% to 43,239.05, the S&amp;P 500 held steady at 5,841.47, and the Nasdaq inched up by 0.04% to close at 18,373.61.
 These are the top stocks that gained the attention of retail traders and investors throughout the day:
Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)
Netflix shares fell by 2.04% to close at $687.65. The streaming giant reported <a href="https://www.benzinga.com/news/earnings/24/10/41391637/netflix-q3-earnings-revenue-beats-eps-tops-q4-guidance-projects-subscriber-boost-from-squid-game-nf">third-quarter revenue</a> of $9.825 billion, a 15% increase year-over-year, beating the Street consensus estimate. The streamer added 5.07 million paid subscribers, bringing its total to 282.72 million. Earnings per share also exceeded estimates, while ad-supported plans represented over 50% of new sign-ups. The company is projecting further revenue growth and strong content releases in the fourth quarter.
Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)
TSMC shares soared by 9.79% to close at $205.84. The company reported consolidated third-quarter revenue of NT$759.69 billion ($23.50 billion), up 39% year-over-year, beating consensus estimates. The <a href="https://www.benzinga.com/news/earnings/24/10/41373163/nvidia-supplier-tsmc-reports-q3-revenue-earnings-beat-amid-rising-demand-for-ai-chips">strong demand for advanced processor node technologies</a> used in AI applications contributed to the impressive results.
American Express Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)
See Also: <a href="https://www.benzinga.com/news/24/10/41354045/as-boeing-workers-enter-second-month-of-strike-rival-airbus-reportedly-plans-to-cut-2-500-jobs?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">As Boeing Workers Enter Second Month Of Strike, Rival Airbus Reportedly Plans To Cut 2,500 Jobs</a>
American Express shares rose by 1.46% to close at $285.78. The company is set to report its third-quarter earnings on Oct. 18, with Wall Street expecting $3.80 in earnings per share and $16.67 billion in revenues. The <a href="https://www.benzinga.com/news/earnings/24/10/41382894/american-express-shows-bullish-signals-ahead-of-q3-earnings-but-analysts-hold-back">stock is up 84.29% over the past year</a>, and 51.1% year-to-date.
Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)
Moderna shares dropped by 4.59% to close at $54.82. The company is facing a patent infringement lawsuit from Northwestern University, alleging that Moderna used the university's lipid nanoparticle (LNP) technology without permission to develop its COVID-19 vaccines. The lawsuit claims that the development of Moderna's COVID-19 vaccine, Spikevax, <a href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology">depended on key technological advancements</a> made at Northwestern.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla shares slipped by 0.20% to close at $220.89. The company has promoted several executives, including Wes Morrill, Milan Kovac, and Ashok Elluswamy, over the past few weeks. Omead Afshar is <a href="https://www.benzinga.com/news/24/10/41378568/tesla-promotes-key-executives-and-gives-them-more-responsibilities-in-leadership-shuffle">now a vice president</a> in charge of sales and manufacturing, with senior executives in North America and Europe reporting to him.
Image Via Shutterstock
Prepare for the day&#8217;s trading <a href=""Premarket">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41391989/exclusive-robinhoods-bitstamp-deal-will-drive-growth-exec-says-what-was-good-for-stocks-we">EXCLUSIVE: Robinhood&#8217;s Bitstamp Deal Will Drive Growth, Exec Says: &#8216;What Was Good For Stocks &#8230; We Brought Into Crypto&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Markets

Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

WIIM

Moderna shares are trading lower. The company was hit with a patent infringement lawsuit from Northwestern University.

Bernstein analyst Courtney Breen initiates coverage on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Market Perform rating and announces Price Target of $55.

Price Target

Initiation

Analyst Ratings

Bernstein Initiates Coverage On Moderna with Market Perform Rating, Announces Price Target of $55

Northwestern University has filed a patent infringement lawsuit against Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), alleging the pharmaceutical company used the university&#8217;s lipid nanoparticle (LNP) technology without permission to develop <a href="https://www.benzinga.com/topic/covid-19">its COVID-19 vaccines.</a>
According to the <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/dwpkkdaxjpm/NORTHWESTERN%20MODERNA%20PATENT%20LAWSUIT%20complaint.pdf" rel="noreferrer noopener">lawsuit</a>, the development of Moderna&#8217;s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41169029/alnylams-concedes-its-patent-infringement-case-against-modernas-covid-19-vaccine" rel="noreferrer noopener">Alnylam&#8217;s Concedes Its Patent Infringement Case Against Moderna&#8217;s COVID-19 Vaccine</a>.
Spikevax contains messenger RNA (mRNA), which instructs cells to create proteins essential for generating an immune response. However, delivering mRNA into cells posed a significant challenge due to cellular resistance. Northwestern scientists overcame this hurdle by developing synthetic LNPs that mimicked the behavior of naturally occurring lipoproteins, allowing the mRNA to enter human cells effectively.
Northwestern&#8217;s research institute, the International Institute for Nanotechnology (IIN), played a crucial role in this breakthrough. Since its inception, IIN has supported over $2.7 billion in research, contributing to numerous medical advancements.
The IIN&#8217;s work has resulted in over 2,000 commercial products and over 40 startups.
Despite being notified of the patents, Moderna has not licensed the LNP technology.
Northwestern now seeks damages for what it claims is ongoing infringement but is not pursuing injunctive relief.
Moderna&#8217;s COVID-19 vaccines have generated significant profits, capturing 45% of the U.S. COVID-19 vaccine market. In 2021, Moderna earned $5.4 billion in U.S. revenues from its vaccines, followed by $4.4 billion in 2022.
The university asserts that Moderna&#8217;s patented technology extends beyond COVID-19 vaccines. The company also incorporates LNP advancements into vaccines for other diseases. Moderna has acknowledged the critical role of LNPs in mRNA vaccine development, referring to the particles as the &#8220;unsung hero&#8221; behind its success.
Recently, GSK Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) filed a lawsuit against&nbsp;Moderna and its affiliates, alleging that Moderna&#8217;s mRNA vaccines infringe on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">patents developed by GSK</a>.
According to GSK, the technology used in Moderna&#8217;s vaccines, including its Spikevax family of vaccines, is based on a platform created by the team led by <a href="https://www.benzinga.com/general/biotech/24/10/41342286/gsk-sues-moderna-alleging-mrna-vaccine-patent-infringement" target="_blank" rel="noreferrer noopener">vaccinologist Christian Mandl</a>.
After London&#8217;s High Court delivered a mixed ruling on two of Moderna&#8217;s patents, Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and&nbsp;Moderna are set for more legal battles over their rival <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">COVID-19 vaccines</a>.
The High Court's ruling declared one of Moderna's mRNA technology patents invalid but upheld another, confirming that Pfizer and BioNTech SE's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) Comirnaty vaccine had infringed on it.
Price Action: MRNA stock is down 1.17% at $56.79 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41379220/elevance-healths-q3-earnings-profit-falls-short-of-expectations-on-higher-medical-costs-issues-soft" target="_blank" rel="noreferrer noopener">Elevance Health&#8217;s Q3 Earnings: Profit Falls Short Of Expectations On Higher Medical Costs, Issues Soft Annual Outlook</a>.</li>
</ul>
Photo: Lutsenko_Oleksandr/Shutterstock.com

Biotech

Health Care

Legal

General

BNTX

Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology

On Wednesday, Cathie Wood&#8217;s Ark Invest made significant trades involving Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) and Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
The SQ Trade
Ark Invest sold off a significant amount of shares in the Jack Dorsey-led Block, despite the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-focused company&#8217;s recent positive second-quarter results. The sale involved 23,473 shares from the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), which, based on the closing price of $73.53 on Wednesday, is valued at approximately $1.72 million. Notably, this is the second day in running when Wood dumped Block shares. On Tuesday, Ark had offloaded 17,816 shares worth $1.28 million.
The MRNA Trade
Ark Invest also sold shares of Moderna Inc from both its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds, totaling 46,186 shares. Based on the closing price of $57.46 per share on Wednesday, the value of this trade is approximately $2.65 million. <a href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations">Moderna recently outlined its post-Covid roadmap</a>, highlighting its mRNA-based pipeline and revised financial plans, which could have influenced Ark&#8217;s decision. Earlier on Tuesday, Wood had sold 24,981 shares of Moderna. worth $1.4 million.
The HOOD Trade
Ark Invest also offloaded 2,636 shares of Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from its ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>). The trade, valued at approximately $71,000 based on the closing price of $26.93 on Wednesday, comes as <a href="https://www.benzinga.com/fintech/24/10/41371235/robinhood-announces-futures-trading-index-options-trading">Robinhood announced the launch of futures trading and index options trading</a>, marking a major expansion of the platform&#8217;s offerings.
Other Key Trades: 
<ul>
<li>Ark Invest bought shares of Intellia Therapeutics Inc (NTLA) and shares of CRISPR Therapeutics AG (CRSP) for its ARKK fund. </li>
<li>It also purchased shares of Tempus AI Inc (TEM) for the ARKK fund and shares for the ARKG fund. For its ARKQ fund, Ark sold shares of Markforged Holding Corp (MKFG) and shares of Materialise NV (MTLS), while buying shares of Blade Air Mobility Inc (BLDE).</li>
</ul>
Image via Wikimedia Commons
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41350336/elizabeth-warren-says-rival-john-deaton-wants-to-go-to-washington-to-fight-for-his-crypto-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says Rival John Deaton Wants To Go To Washington To Fight For His &#8216;Crypto Buddies&#8217; — Republican Fires Back, Claiming He&#8217;s Upset Crypto Billionaires More Than Anyone Else</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

ETFs

$BTC

ARKG

ARKK

ARKW

HOOD

Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock

On Tuesday, Cathie Wood-led Ark Invest made significant trades, most notably selling off shares of Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>).
The SQ Trade
Ark Invest sold 17,816 shares of the Jack Dorsey-headed Block Inc. from its ARKK fund. This move comes despite Block Inc.&#8217;s recent positive <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40138790/block-inc-earns-analyst-praise-q2-results-showcase-cash-app-growth-strategic-innova">second-quarter results</a>, which showcased growth in its Cash App and strategic innovations. The value of the trade, based on the closing price of $71.79 per share on Tuesday, is approximately $1.28 million.
Significantly, the sale of Block shares came on a day when Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41349325/bitcoin-marches-ahead-ethereum-dogecoin-flat-amid-stocks-reversal-analyst-highlights-facto">moved up</a>. The apex cryptocurrency has been on a tear this week. Dorsey has envisioned a transformative future for Block, moving beyond payments to focus on Bitcoin and the potential for building a new banking model. Recently, Block took a significant step into the crypto realm by securing its first major deal in crypto mining with Core Scientific, which J.P. Morgan estimates could <a href="https://www.benzinga.com/partner/biotech/24/10/41311218/redhill-biopharma-secures-u-s-government-funding-through-barda-to-advance-opaganib-for-ebola-trea">generate between $225 million and $300 million</a>. While Dorsey&#8217;s commitment to Bitcoin is evident, analysts remain cautious, emphasizing the need for solid profit margins to validate this ambitious direction
Other Key Trades: 
<ul>
<li>Ark Invest bought shares of Tempus AI Inc. The firm purchased 17,082 shares from its ARKG fund and 75,991 shares from its ARKK fund.</li>
<li>Ark Invest bought shares of Blade Air Mobility Inc. (BLDE) from its ARKQ fund. The firm sold shares of Materialise NV (MTLS) from its ARKQ fund. Ark Invest bought 1,000 shares of Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from its ARKX fund.</li>
<li>Significantly, Ark also sold shares of COVID-19 vaccine maker Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). The firm sold a total of 24,981 shares from ARKK and ARKG funds worth $1.4 million approximately.</li>
</ul>
Image via Shutterstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41303723/jim-cramer-says-im-worried-about-boeing-after-plane-maker-lays-off-17-000-employees-amid-safety-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Says &#8216;I&#8217;m Worried&#8217; About Boeing After Plane Maker Lays Off 17,000 Employees Amid Safety And Financial Woes: &#8216;A Very Jarring Series Of News Tonight&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood's Ark Offloads $1.28M In Jack Dorsey's Block Shares Despite Bitcoin Rally

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 15.81% on an annualized basis producing an average annual return of 29.89%. Currently, Moderna has a market capitalization of $22.10 billion. 
Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $3,869.68 today based on a price of $57.50 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729024220_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today

GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) has filed a lawsuit against Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and its affiliates, alleging that Moderna&#8217;s mRNA vaccines infringe on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39602190/london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents" rel="noreferrer noopener">patents developed by GSK</a>.
According to GSK, the technology used in Moderna&#8217;s vaccines, including its Spikevax family of vaccines, is based on a platform created by the team led by vaccinologist Christian Mandl.
GSK claims Moderna has profited billions from using this technology without proper acknowledgment or licensing.
GSK <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/egvbjynkevq/GSK%20MODERNA%20LAWSUIT%20complaint.pdf" rel="noreferrer noopener">asserts</a> that its scientists, including Christian Mandl, Andrew Geall, and others, pioneered mRNA vaccine technology more than a decade before the COVID-19 pandemic.
These scientists developed formulations combining lipids and mRNA molecules to create vaccines that trigger immune responses against viral infections. The GSK team filed patents related to these inventions in 2010, laying the groundwork for modern mRNA vaccine development.
The groundbreaking aspect of GSK&#8217;s invention lies in the flexibility and speed of its platform, which allows for the quick development of vaccines for various viral pathogens.
Notably, GSK points to the rapid creation of an mRNA vaccine candidate during the 2013 influenza outbreak in China, setting a record for vaccine development time. The scientific journal Nature highlighted the platform&#8217;s versatility and speed, which noted that many mRNA companies now utilize variations of the Mandl team&#8217;s technology.
Despite the significance of these advancements, GSK argues that Moderna has never acknowledged its reliance on GSK&#8217;s patented platform. Instead, Moderna has focused on promoting the speed and efficiency of its mRNA vaccines, such as Spikevax, which have been modified to address different strains of the SARS-CoV-2 virus. GSK now seeks to recover royalties for what it claims are unauthorized sales of vaccines that infringe on its intellectual property.
The lawsuit emphasizes that Moderna has benefited financially from GSK&#8217;s patented technology without securing the necessary licenses. GSK aims to secure compensation for Moderna&#8217;s use of its innovative mRNA vaccine platform.
Earlier this year, in Delaware federal court, GSK sued Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), alleging patent infringement concerning the mRNA technology used in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38440329/whats-going-on-with-pfizer-stock-on-thursday" rel="noreferrer noopener">the COVID-19 vaccines</a>.&nbsp;
Price Action: GSK stock is down 0.40% at $38.98, and MRNA stock is down 0.69% at $57.33 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41339315/nvidia-and-intel-competition-threaten-amds-growth-analyst-says" target="_blank" rel="noreferrer noopener">Nvidia and Intel Competition Threaten AMD&#8217;s Growth, Analyst Says</a>.</li>
</ul>

Media

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement

18 analysts have expressed a variety of opinions on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $102.44, a high estimate of $178.00, and a low estimate of $55.00. This current average represents a 20.12% decrease from the previous average price target of $128.24. 
<img src="https://www.benzinga.com/files/images/story/2024/1729011623_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Moderna by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$139.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$178.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$214.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Moderna's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Moderna's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>Delving into Moderna's Background</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Moderna: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Moderna faced challenges, resulting in a decline of approximately -30.06% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Moderna's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -578.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.43%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.89%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Moderna adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 18 Analyst Insights On Moderna

Jefferies analyst Michael Yee maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Hold and lowers the price target from $65 to $55.

Jefferies Maintains Hold on Moderna, Lowers Price Target to $55

GlaxoSmithKline Sues Moderna For U.S. Patent Infringement Over mRNA Technology In Covid-19 Vaccines

On Thursday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). This decision comes amidst a backdrop of mixed analyst sentiments and Moderna&#8217;s recently unveiled post-COVID roadmap.
The Moderna Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) sold a total of 160,994 shares of Moderna. The value of the trade, based on Moderna&#8217;s closing price of $56.83 on the day of the trade, is approximately $9.15 million.
Moderna&#8217;s stock has been under scrutiny following its recent announcement of a <a href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations">revised financial plan</a> and updates to its mRNA-based pipeline. CEO Stéphane Bancel highlighted the company&#8217;s success in respiratory vaccines and outlined a focus on five non-respiratory products aiming for approvals by 2027.
However, the biotech company&#8217;s future prospects have elicited <a href="https://www.benzinga.com/insights/analyst-ratings/24/09/40862440/16-analysts-have-this-to-say-about-moderna">mixed reactions</a> from analysts. Over the past three months, 16 analysts have shared their evaluations, with the average 12-month price target standing at $111.50, a decrease of 18.06% from the previous average.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41245350/nvidia-poised-to-overtake-apple-as-worlds-most-valuable-company-how-much-jensen-huangs-company-n?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia Poised To Overtake Apple As World&#8217;s Most Valuable Company: How Much Jensen Huang&#8217;s Company Needs To Gain By Wednesday</a> 
Other Key Trades:
ARK Autonomous Technology &amp; Robotics ETF (ARKQ) bought 3,589 shares of Advanced Micro Devices Inc (AMD) worth $589,242.
Ark Invest&#8217;s ARKG and ARKK bought a total of shares of 10X Genomics Inc (TXG). 
ARKK also purchased shares of CRISPR Therapeutics AG (CRSP). 
Blade Air Mobility Inc (BLDE), and 3D Systems Corp (DDD) while selling shares of Materialise NV (MTLS) and Markforged Holding Corp (MKFG).
Image via Flickr/ WEF
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41274321/trump-considers-pro-crypto-vivek-ramaswamy-for-key-administration-role-hell-do-a-better-jo?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Considers Pro-Crypto Vivek Ramaswamy For Key Administration Role: &#8216;He&#8217;ll Do A Better Job Than Anybody&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table

On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could revolutionize cancer treatment, joining in the global trend as pharmaceutical companies across the world turn to oncology for economic growth and opportunity to make history. As they continue to chase slices of covid vaccine revenue,&nbsp;Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) and Moderna&nbsp;Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) have already turned to the pursuit of revolutionizing cancer therapies in order to create their new growth chapter in the post-COVID era. Therefore, mRNA technology, personalization of&nbsp;treatments and immunotherapy promise to fuel science to finally advance in the cancer battle.&nbsp;
More about UK&#39;s&nbsp;&pound;9 million project that focuses on ways of using immunotherapy&nbsp;to fight cancer.&nbsp;
The partnership between the Francis Crick Institute, five&nbsp;NHS trusts, charities and bioscience companies&nbsp;will take place over the course of four years, examining the effectiveness of new immunotherapy treatments along with exploring new ways of cancer detection. The project is part of a &pound;118 million incentive to create five new hubs across the UK to develop new health technologies that includes AI cancer diagnostics. Named as&nbsp;The Manifest project, the Crick Institute will lead the way in examining tumours and blood samples from 3,000 patients who have suffered from cancer in an effort to find which biomarkers &ndash; such as genes, proteins or molecules&nbsp;could indicate undetected cancer as well as the possibility of a relapse. Hopefully, the study will pave the way for the development of further immunotherapy treatment that would help the patients&rsquo; bodies to fight cancer as oppposed to aggressive treatments used nowadays which sometimes cause more harm than good.
Immunotherapy has already proven its effectiveness in cancer treatment.&nbsp;
Merck &amp; Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) has already made its mark in immunotherapy with its&nbsp;Keytruda treatment. It also integrated it within a combined treatment for melanoma, together with the experimental mRNA vaccine it developed with Moderna. During summer, Moderna and Merck revealed encouraging data in patients who suffered with this deadly form of cancer. Moderna and Merck reported the combination of their experimental vaccine improved survival rates with almost 75% of patients being cancer-free during the two-and-a-half-year timeframe. The overall survival rate of patients that underwent the combined therapy that Moderna and Merck developed was as high as 96% during that same time frame.
A German company has already revolutionized early cancer detection
Molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>), released a non-invasive test for one of the most common cancers in July this year. Allowing for early detection of colorectal cancer, ColoAlert is currently being commercialized across Europe and in select international markets while Mainz Biomed paves the way to the U.S. market with FDA evaluating its ReconAAsense clinical study. Today, Mainz Biomed revealed that there is increasing demand from both existing and prospective laboratory partners for its enhanced version of the ColoAlert that is set to become the standard offering to which existing partners will transition to. By integrating the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, an advanced AI and machine learning algorithm, studies showed that ColoAlert detects colorectal cancer with 97% sensitivity while also detecting a pre-cancerous condition called advanced adenomas with 88% sensitivity, with specify of 93%. Therefore, Mainz Biomed even tackled the area of cancer prevention and with a non-invasive test that can be taken easily by all those who are dreading getting a colonoscopy.
At the very least, the above innovations provide hope to all those suffering from this dreadful condition. While saving lives, pharmaceutical companies who succeed to revolutionize cancer treatment will also bring their domestic economies massive opportunities for growth, securing their status as a medical powerhouse as cancer is the one battle that science and technology has been failing to win for way too long.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Penny Stocks

MYNZ

Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer

Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna.
Looking at options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $1,639,604 and 5, calls, for a total amount of $239,740.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $120.0 for Moderna over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Moderna stands at 1500.79, with a total volume reaching 847.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $60.0 to $120.0, throughout the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728493295_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$62.1</td>
<td>$60.95</td>
<td>$62.1</td>
<td>$120.00</td>
<td>$993.6K</td>
<td>582</td>
<td style="text-align: right;">160</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.55</td>
<td>$13.35</td>
<td>$13.4</td>
<td>$60.00</td>
<td>$201.0K</td>
<td>8</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$20.8</td>
<td>$20.65</td>
<td>$20.8</td>
<td>$75.00</td>
<td>$122.7K</td>
<td>874</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$27.0</td>
<td>$26.95</td>
<td>$26.95</td>
<td>$85.00</td>
<td>$102.4K</td>
<td>3.1K</td>
<td style="text-align: right;">35</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.35</td>
<td>$5.2</td>
<td>$5.35</td>
<td>$95.00</td>
<td>$90.4K</td>
<td>218</td>
<td style="text-align: right;">169</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Current Position of Moderna</h3>
<ul>
<li>Currently trading with a volume of 1,302,422, the MRNA's price is up by 0.96%, now at $58.95. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $89.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for Moderna, targeting a price of $60. 
&#x2A; An analyst from Jefferies downgraded its action to Hold with a price target of $65. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Moderna, which currently sits at a price target of $110. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Moderna, maintaining a target price of $75. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Moderna, targeting a price of $139. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On Moderna

Moderna's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NYSE">MRNA</a>) short percent of float has risen 7.75% since its last report. The company recently reported that it has 27.61 million shares sold short, which is 9.45% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Moderna Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728414913_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Moderna has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Moderna's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Moderna's peer group average for short interest as a percentage of float is 5.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(MRNA) - Analyzing Moderna's Short Interest

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Nkarta Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>)</h3>
<ul>
<li>On Aug. 13, Nkarta reported better-than-expected second-quarter EPS results. &#8220;Patients remain our focus, and early execution on our clinical trials across disease areas is a testament to that commitment,&#8221; said Paul J. Hastings, CEO of Nkarta. &#8220;NKX019 has the potential to reach people living with a wide range of autoimmune diseases, and we will continue to evaluate ways to maximize our impact in this field. Our cellular engineering enables us to evaluate a reduced toxicity lymphodepletion regimen, to limit hospitalization and patient burden, and spare the complications of other agents.&#8221; The company's stock fell around 35% over the past month and has a <a href="https://www.benzinga.com/quote/NKTX">52-week low of $1.32</a>.</li>
<li>RSI Value: 29.34</li>
<li>NKTX Price Action: Shares of Nkarta fell 2% to close at $3.84 on Monday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">latest NKTX news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="880" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041306/image-43.png" alt="" class="wp-image-584971" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041306/image-43.png 880w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041306/image-43-300x287.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041306/image-43-768x734.png 768w" sizes="(max-width: 880px) 100vw, 880px" /></a></figure>
<h3 class="wp-block-heading">Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;</h3>
<ul>
<li>On Sept. 30, Moderna said it has dosed the first US participant in Nova 301 Phase 3 trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. &#8220;Norovirus is a significant public health concern that affects millions of people worldwide each year, leading to severe symptoms and, in some cases, hospitalization,&#8221; said Stéphane Bancel, CEO of Moderna. &#8220;By advancing our investigational norovirus vaccine into a pivotal Phase 3 trial, we are one step closer to potentially providing a new tool to prevent infection from this highly contagious virus, which places a significant burden on health systems globally.&#8221; The company's stock fell around 23% over the past month. It <a href="https://www.benzinga.com/quote/mrna">has a 52-week low</a> of $58.33.</li>
<li>RSI Value: 24.97</li>
<li>MRNA Price Action: Shares of Moderna fell 2.5% to close at $58.72 on Monday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">MRNA stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041343/image-44.png" alt="" class="wp-image-584972" style="width:674px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041343/image-44.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041343/image-44-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041343/image-44-768x709.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">AMN Healthcare Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>)</h3>
<ul>
<li>On Oct. 7, B of A Securities analyst Kevin Fischbeck downgraded AMN Healthcare Services from Neutral to Underperform and lowered the price target from $65 to $48. The company's shares fell around 15% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/mrna">low of $36.50.</a></li>
<li>RSI Value: 29.20</li>
<li>AMN Price Action: Shares of AMN Healthcare gained 0.8% to close at $38.64 on Monday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1">breakout in AMN shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="882" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041448/image-45.png" alt="" class="wp-image-584975" style="width:653px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041448/image-45.png 882w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041448/image-45-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/08041448/image-45-768x720.png 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41213879/top-3-financials-stocks-that-may-jump-this-quarter">Top 3 Financials Stocks That May Jump This Quarter</a></li>
</ul>

Pre-Market Outlook

NKTX

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

CVAC

Reuters Reported Pfizer, Biontech Win Bid In UK Court To Invalidate Curevac's Patents Over MRNA Technology In Covid-19 Vaccines

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$20.00</td>
<td>$41.4K</td>
<td>389</td>
<td>5.5K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$260.00</td>
<td>$25.2K</td>
<td>849</td>
<td>1.4K</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$190.00</td>
<td>$27.6K</td>
<td>4.0K</td>
<td>718</td>
</tr>
<tr>
<td>NVCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$13.00</td>
<td>$27.6K</td>
<td>110</td>
<td>691</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$490.00</td>
<td>$30.8K</td>
<td>250</td>
<td>161</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>6.6K</td>
<td>113</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$70.7K</td>
<td>2.6K</td>
<td>92</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$32.2K</td>
<td>1.8K</td>
<td>66</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$100.00</td>
<td>$26.7K</td>
<td>420</td>
<td>59</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$600.00</td>
<td>$40.6K</td>
<td>464</td>
<td>51</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 901 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.4K, with a price of $46.0 per contract. There were 389 open contracts at this strike prior to today, and today 5520 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 120 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $210.0 per contract. There were 849 open contracts at this strike prior to today, and today 1476 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a put option sweep that happens to be bullish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 60 contract(s) at a $190.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $460.0 per contract. There were 4070 open contracts at this strike prior to today, and today 718 contract(s) were bought and sold. 
• For NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we notice a put option sweep that happens to be bearish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 690 contract(s) at a $13.00 strike. This particular put needed to be split into 63 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $40.0 per contract. There were 110 open contracts at this strike prior to today, and today 691 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bullish, expiring in 39 day(s) on November 15, 2024. This event was a transfer of 16 contract(s) at a $490.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $1930.0 per contract. There were 250 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 44 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $890.0 per contract. There were 6607 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 102 day(s) on January 17, 2025. This event was a transfer of 68 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $70.7K, with a price of $1040.0 per contract. There were 2682 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 43 contract(s) at a $45.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $750.0 per contract. There were 1834 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option sweep with bullish sentiment. It expires in 347 day(s) on September 19, 2025. Parties traded 50 contract(s) at a $100.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $535.0 per contract. There were 420 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bullish, expiring in 466 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $40.6K, with a price of $2030.0 per contract. There were 464 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NVCR

SAVA

10 Health Care Stocks Whale Activity In Today's Session

How is QQQ stock faring? The Invesco QQQ ETF is up 0.03% in the past five days and has risen about 22.01% year-to-date.   According to TipRanks' un...

QQQ ETF Update, 10/16/2024

Most shorted S&P 500 stocks in September

Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has halted one of the compan...

Novavax (NASDAQ:NVAX) Stock Drops 18% as Clinical Trial Halted

Novavax (NASDAQ:NVAX) Stock Drops 18% after Clinical Trial Is Halted

Lilly, Gilead, Amgen started at outperform by Bernstein

How is SPY stock faring? The SPDR S&P 500 ETF Trust  is up 0.06% in the past 5 days and has risen about 23.13% year-to-date. According to TipRanks'...

SPY ETF Update, 10/17/2024

Jefferies analyst Michael Yee maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $55.00. The company's sh...

Moderna (MRNA) Receives a Hold from Jefferies

How is VOO stock faring? The Vanguard S&P 500 ETF is up 0.1% in the past five days and has risen 37.33% over the past year. According to TipRanks' ...

VOO ETF Update, 10/18/2024

BioNTech and Moderna: A tale of two mRNA developers

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here's an updated look at the top 10 worst performing large-caps, along with their one-year price returns.

Large-Cap Stocks In Trouble - Saturday, Oct. 19

ABBV

ALLE

AMGN

APTV

ASML

AXON

BIIB

BKNG

CHTR

DXCM

FOXA

FTNT

GILD

INTC

NVAX

PARA

PAYC

PLTR

POOL

SMCI

SMMT

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm

MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights

MRNA DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA

Shareholders of Moderna, Inc. Should Contact The Gross Law Firm Before October 8, 2024 to Discuss Your Rights - MRNA

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Moderna, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA

The Gross Law Firm Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MRNA

Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Comments

Moderna

Actualités

Dernières nouvelles pour Moderna (NASDAQ:MRNA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL